LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

LLY

885.74

+0.89%↑

JNJ

242.36

+0.87%↑

ABBV

213.05

+1.61%↑

NVS

150.35

+1.42%↑

MRK

117.86

-1.52%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.17

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.1400000000000001

Max

1.18

Põhinäitajad
By Trading Economics
Sissetulek	2.7M -24M
Aktsiakasum	-0.354
Töötajad	49
EBITDA	-5.3M -28M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+128.21% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-1.2M 80M
Eelmine avamishind	1.17
Eelmine sulgemishind	1.17

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. märts 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30. märts 2026, 22:36 UTC

Uudisväärsed sündmused

Australian Government Rules Out Boots on the Ground in the Middle East

30. märts 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30. märts 2026, 21:00 UTC

Tulu

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30. märts 2026, 20:15 UTC

Uudisväärsed sündmused

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30. märts 2026, 23:40 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. märts 2026, 23:40 UTC

Market Talk

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30. märts 2026, 23:36 UTC

Market Talk

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30. märts 2026, 23:12 UTC

Market Talk

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30. märts 2026, 22:49 UTC

Market Talk

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30. märts 2026, 22:44 UTC

Market Talk

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30. märts 2026, 22:43 UTC

Market Talk

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30. märts 2026, 22:42 UTC

Market Talk

South32 Should Go for Growth, Says New Bull -- Market Talk

30. märts 2026, 22:18 UTC

Market Talk

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30. märts 2026, 22:05 UTC

Market Talk

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30. märts 2026, 21:58 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Financial Agrees to Buy Bell Partners for $350M

30. märts 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30. märts 2026, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30. märts 2026, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30. märts 2026, 21:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. märts 2026, 21:25 UTC

Market Talk

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30. märts 2026, 21:03 UTC

Omandamised, ülevõtmised, äriostud

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30. märts 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. märts 2026, 20:09 UTC

Tulu

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30. märts 2026, 20:00 UTC

Uudisväärsed sündmused

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

128.21% tõus

12 kuu keskmine prognoos

Keskmine 2.67 USD 128.21%

Kõrge 3 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.